SecBot SecBot
6-K ·Filed Jun 1, 2026

BNTX

BioNTech SE
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago SEC0001776985-26-000039
Notable filing: 6-K
Actionable Insight ▲ Bullish

The data are encouraging but early (Phase 2, n=40). Monitor for Phase 3 readouts from the ROSETTA Lung-02 trial and the two other NSCLC Phase 3 trials (ROSETTA Lung-201 and -202). The broad registrational program (7 Phase 3 trials) suggests high optionality, but de-risking requires larger datasets. No financial impact until regulatory approval.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$91.70
T+0 close · Jun 1, 2026 · via day close
Latest settled
+24.37%
T+60 · $114.05
Vs SPY
+23.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $91.70entry
  2. T+1 · 6mo ago −2.79%α −2.94% · $89.14
  3. T+5 · 5mo ago −3.95%α −1.20% · $88.08
  4. T+20 · 5mo ago +1.47%α +2.77% · $93.05
  5. T+60 · 3mo ago +24.37%α +23.14% · $114.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in first-line non-small cell lung cancer. The data showed a confirmed objective response rate of 57.1% in non-squamous and 68.4% in squamous NSCLC, with a 100% disease control rate, and a manageable safety profile. This is a positive clinical update for a key pipeline asset, but the data are early-stage (Phase 2, n=40) and the stock impact is likely modest given the pre-revenue nature of the company.

Key Facts

  • Interim Phase 2 data from ROSETTA Lung-02 trial of pumitamig (BNT327/BMS-986545) plus chemotherapy in first-line advanced NSCLC.
  • Confirmed objective response rate (cORR) of 57.1% in non-squamous and 68.4% in squamous NSCLC; disease control rate (DCR) of 100%.
  • At the lower dose, cORR was 63.6% for non-squamous and 72.7% for squamous subtypes.
  • cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%).
  • Grade 3 treatment-related adverse events in 48.8% of patients; treatment discontinuation in 9.3%.
  • Phase 3 part of ROSETTA Lung-02 is actively enrolling; two additional global Phase 3 trials in NSCLC are also enrolling.
  • Seven global Phase 3 trials with registrational potential are ongoing across multiple indications.

Financial Impact

No financial figures provided in the filing. Pumitamig is an investigational asset with no approved products or disclosed revenue.

Risk Factors

  • Phase 2 data are from a small sample (n=40) and may not replicate in larger Phase 3 trials.
  • Safety profile includes Grade 3 TRAEs in 48.8% of patients and a 9.3% discontinuation rate, which could limit commercial potential.
  • Pumitamig is pre-revenue; BioNTech's stock remains tied to pipeline milestones and COVID vaccine revenue trends, not disclosed here.
  • Competition from existing PD-(L)1 and VEGF inhibitors (e.g., Keytruda, Avastin) and other bispecifics in development.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000039
Document: form6-kascopumitamignsclc1.htm0001776985-26-000039
Document: 0001776985-26-000039-index-headers.html0001776985-26-000039
Document: 0001776985-26-000039-index.html0001776985-26-000039
Document: 0001776985-26-000039.txt0001776985-26-000039

Track record

38 reports on BNTX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026